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The advent of human pluripotent cell lines holds enormous promise for the development of cell 48 
therapies to treat degenerative disease. Safety, however, is a crucial pre-condition for clinical 49 
application. Numerous groups have attempted to eliminate potentially harmful cells through the use 50 
of suicide genes1; however, none of these efforts quantitatively define safety. Here, we show a 51 
concept for the protection of a suicide transgene system from inactivation and its realisation with 52 
genome engineering strategies. The strategy behind our fail-safe (FS) design is to create a 53 
transcriptional link between the suicide gene herpes simplex virus-thymidine kinase (HSV-TK) and 54 
a cell division essential gene, Cyclin-Dependent Kinase 1 (CDK1). Furthermore, we add a 55 
quantitative measure to cell therapy safety as the function of the cell number needed for a therapy 56 
and the type of genome editing performed. Even with the highly conservative estimates described 57 
here, we anticipate that our solution and the quantification of safety will rapidly accelerate the entry 58 
of cell-based medicine to the clinic. 59 
 60 
Most randomly integrated transgenes are not stably expressed in all cells. The transfected cell 61 
population will show variegated expression as a result of epigenetic and genetic modifications, 62 
developmental regulation, mutations, and/or complete loss of the transgene2-4. To alleviate these 63 
mechanisms, we generated a transcriptional link between a cell division essential locus (CDEL) and a 64 
drug-inducible suicide system (SU), resulting in a CDEL-SU allele (Fig. 1a). In this design, the expression 65 
of the CDEL and SU are tightly linked together, and if required, the dividing cells of a graft can be 66 
eliminated or arrested through treatment with the SU prodrug. With an SU placed in a CDEL essential for 67 
cell-life, the entire graft could be eliminated regardless of its proliferative status. 68 
According to the engineering definition, fail-safe systems are designed to mitigate potential harm 69 
caused by a system failure. Using this terminology, a cell population is considered fail-safe if all of the 70 
cells within the population contain a functional SU. The fail-safe level (FSL) is defined as a number. It 71 
indicates that the odds of using a non-FS batch of cells for therapy is one out of this number (Fig. 1b), 72 
such as one out of a thousand (FSL=1,000) or one out of a million (FSL=1,000,000) batches. Here, we used 73 
various in vitro and in vivo experiments as well as mathematical modelling to define the FSL that needs to 74 
be satisfied for future cell therapies to be designated as safe. 75 
To generate a list of CDEL candidates, we cross-referenced genes whose knock-out has an early 76 
embryonic lethal phenotype in mice (http://www.informatics.jax.org/phenotypes.shtml) with data from a 77 
genome-wide CRISPR/Cas9 mutagenesis screen for essential genes in human cancer cell lines5. We found 78 
167 genes with a high-fitness score (< -1.0)5 that also have a known early-embryonic lethal phenotype 79 
(Supplementary Table 1). For this study, we chose CDK1 as our prototype CDEL and an optimised mutant 80 
version of HSV-TK, TK.0076 (TK from now on), as the SU prototype. Genetic studies have shown that 81 
CDK1 is an essential kinase7. Its absence causes a block in the G2/M transition of the cell cycle, and other 82 
CDKs are not able to rescue its deficiency8,9. TK has been extensively used for cell ablation10, and its 83 
mechanism of action in the presence of its clinically-approved prodrug ganciclovir (GCV), is well 84 
characterised11. Importantly, CDK1 and the linked TK are not expressed in non-dividing cells9, thus 85 
eliminating the potential immunogenicity of the viral TK protein12 in quiescent donor cells. 86 
To generate a transcriptional link between CDK1 and TK (Fig. 1c), we used CRISPR/Cas9-assisted 87 
genome targeting to insert TK into the 3’ untranslated region (3’UTR) of CDK1 in mouse C213 (Extended 88 
Data Fig. 1a-d, 2a-c), human H114 (Extended Data Fig. 1e-i, 3a-f) and human CA115 (Extended Data Fig. 89 
4a-e) embryonic stem (ES) cells. Next, we determined the optimal GCV concentration for the 90 
heterozygous CDK1-TK mouse and human ES cells in vitro (Extended Data Fig. 2d, 3h), and then 91 
subsequently tested if we could control the growth of teratomas generated from these lines. Subcutaneous 92 
grafting of mouse ES cells into isogenic C57BL/6N recipients, and human ES cells into immunodeficient 93 
NOD scid gamma (NSG) recipients, resulted in teratoma formation with the expected efficiency (Extended 94 
Data Fig. 2e, 3g, 4d). When the volume of these tumours reached 500 mm3 (considered as day 0), we 95 
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administered GCV daily by intraperitoneal injection for up to four weeks.  Exposure to GCV rendered the 96 
C2 ES cell-derived teratomas dormant, without any sign of growth rebound following the treatment (Fig. 97 
1d, e and Extended Data Fig. 5a). The heterozygous H1 ES cell-derived teratomas in NSG mice responded 98 
similarly, albeit, in most of the cases, repeated and more extended GCV treatments were required to 99 
stabilise the teratoma size (Fig. 1f and Extended Data Fig. 5c). The observed decrease in teratoma size 100 
following GCV re-administration (Extended Data Fig. 5c) indicates that quiescent or slow-dividing cells 101 
within the teratoma began proliferating following drug withdrawal, and consequently, expressed TK and 102 
became sensitive to GCV. Furthermore, we found that the volume of the human teratomas frequently 103 
increased in the later phase of the experiments (Extended Data Fig. 5d); however, in agreement with 104 
previous reports16,17, this increase was the result of extensive cyst formation (Extended Data Fig. 5d) and 105 
not solid tissue growth. The induced long-term dormancy of the teratomas was encouraging but also 106 
unexpected as  we predicted that such a large ES cell-derived tissue (~109 cells18) would contain hundreds 107 
of cells capable of escaping the SU through different types of mutations, such as silencing mechanisms 108 
and loss-of-heterozygosity (LOH). Within the well-encapsulated teratoma, however, it is likely that these 109 
assumed resistant cells (escapees) were eliminated by the known bystander killing effect of the TK/GCV 110 
system19. 111 
To further investigate the capacity of the FS system to control cell proliferation, we also performed a 112 
breast cancer transplantation assay using heterozygous FS mammary epithelial tumour cells20. Upon 113 
transplantation in an isogenic setting, we observed that after a delayed period (~100 days) the 114 
heterozygous FS tumours became resistant to GCV and continued growing in the presence of the drug 115 
(Extended Data Fig. 6a,b). 116 
To identify escapees appearing in the expansion of heterozygous FS ES cells, we designed an in 117 
vitro experiment to mitigate the bystander killing effect (Extended Data Fig. 7a,b) and subsequently 118 
characterised the resistance mechanism in the eight independent clonal escapee-lines we obtained from 119 
120 million cells. To determine if the escapee-generating mechanism was due to large genomic changes or 120 
Cdk1-TK locus-specific, we analysed the copy number (CN) of Cdk1, the TK transgene, and six additional 121 
endogenous genes all located on chromosome 10 (Fig. 1i, Extended Data Fig. 7d). Interestingly, this 122 
analysis revealed that only one escapee (E3 in Fig. 1i) contained the TK gene (Extended Data Fig. 7c). 123 
Further analyses did not detect mutations in the coding region of either Cdk1 or TK (data not shown) but 124 
found the expression level of this allele was compromised and rendered the cells GCV resistant (Extended 125 
Data Fig. 7e). Another escapee, E5, was the result of a regional deletion involving the Cdk1-TK locus, 126 
and this led to at least an 18.5 Mbp hemizygous region in the wild type chromosome (predicted by CN=1 127 
in Sim1, Rhobtb1, Cdk1 and Ank3 genes (Fig. 1i, Extended Data Fig. 7d). Regarding the other six clones, 128 
the diploidy (CN=2) of all of the examined endogenous chromosome 10 genes and the lack (CN=0) of TK 129 
suggested that these six escapees were formed by diploid LOH (dLOH). This was likely due to mitotic 130 
recombination events or chromosomal non-disjunction which homozygosed the wild type Cdk1 allele in 131 
a diploid form. In summary, our data indicate that dLOH is the dominant mechanism of losing the Cdk1-132 
TK allele in heterozygous ES cells. This finding is consistent with a study of mouse Aprt heterozygous 133 
cells, where dLOH accounted for 78% of the observed loss of gene function events21. 134 
To mitigate the generation of escapees by dLOH, we established both mouse and human ES cells 135 
homozygous for the CDK1-TK allele (Extended Data Fig. 2a-c, 3a-h, 4a-e). As expected, we were unable 136 
to identify any escapees when we repeated the above experiment (Extended Data Fig. 7b). It was not 137 
surprising that the homozygous ES cell-derived teratomas behaved similarly to the heterozygous 138 
teratomas; a brief GCV treatment was sufficient to render these tissues dormant (Fig. 1g,h, Extended Data 139 
Fig. 5b,e). As observed for the human heterozygous lines, cyst formation also occurred in the human 140 
homozygous teratomas (Extended Data Fig. 5e). Furthermore, we also generated homozygous FS 141 
mammary tumour cells and, following transplantation, observed that the size of these tumors could be 142 
reduced and their growth restrained through GCV administration (Extended Data Fig. 6c).  The observed 143 
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growth rebound following GCV withdrawal was not surprising as slow-dividing or quiescent, tumour-144 
prone MMTV-PyMT cells survive GCV administration and can start growing in the absence of the drug. 145 
Nevertheless, even in this non-clinical, extreme situation where a tumour cell line is used for cell 146 
transplantation, the homozygous FS system is still capable of managing and controlling tumour growth. 147 
Since we were unable to identify any escapees appearing in homozygous FS ES cell expansion, we used 148 
Monte Carlo (MC) simulation to estimate the odds of generating an escapee in this scenario. The model 149 
considers three different types of mutations which could affect the function of the CDEL-SU link (Fig. 150 
2a). Type 1 mutations (su1) render the SU non-functional while keeping the linked CDEL 151 
operational. Type 2 mutations (su2) eliminate both SU and CDEL functionality through epigenetic or 152 
genetic changes to the entire locus, including a hemizygous LOH-dependent mechanism. Type 3 153 
mutations remove a functional CDEL-SU allele by dLOH. 154 
To estimate the probabilities of the type 1, 2 and 3 mutations (p1, p2 and p3, respectively) per cell 155 
generation (Fig. 2a), we used our targeted human H1 CDK1-TK-mCherry/CDK1-TK-EGFP dichromatic 156 
cell line, as most mutations in either CDK1-TK allele result in monochromatic cells. We grew 21 parallel 157 
cultures from a single dichromatic cell to an average of 5x106 cells per culture (> 22 consecutive 158 
doublings) and determined the number of monochromatic cells in the culture using flow cytometry. Next, 159 
we applied Luria-Delbruck fluctuation analysis22,23 to calculate the sum of the p1+p2+p3 probabilities in 160 
the two CDK1-TK alleles. We found that the mutation rate of losing mCherry was 9.05x10-6 per cell per 161 
division while the mutation rate of losing EGFP was similar at 7.68x10-6 per cell per division (Extended 162 
Data Fig. 8a-b). 163 
To further validate the probabilities of these various mutations, we also analysed published studies 164 
that focused on these events. In mouse ES cells, the mutation rate (p1+p2+p3) of changing from a 165 
dichromatic to a monochromatic phenotype in the Rosa26 locus (mouse Chr. 6) was 1x10-5 per cell, per 166 
division24. Similarly, another study calculated the mutation rate of gene function loss in the Gdf9 locus 167 
(mouse Chr. 11) to be 2.3x10-5 events per cell per division25. Furthermore, the probability of the type 3 168 
mutation, p3 alone, has been calculated as 1x10-5, 7.2x10-6 and 8.5x10-6 in three different studies26-28 by 169 
performing high G418 selection in mouse ES cells. The p1+p2 mutation rate has also been estimated in 170 
the human HPRT locus on the X chromosome to be 1.7-6x10-7 by Luria-Delbruck fluctuation analysis29, 171 
and 5x10-6 through mutation frequency analysis in population datasets30. 172 
Next, we performed MC simulation to establish the FSL of cell batches derived from different 173 
SU genotypes. Based on both published data and our own, we used the values p1=p2=10-6 and p3=2x10-5 174 
per cell per division; all of which are intentional overestimates. Consequently, our calculated FSLs 175 
represent underestimates, being equal or lower than the actual FSL. 176 
In silico, we subsequently generated a sufficient number of cell batches that were expanded from 177 
a single cell with an intact SU system.  In every doubling, the model permits allele transitions (Fig. 2b) 178 
which determine the transition graph (depicted in Fig. 2c); reflecting the genotype change that could occur 179 
during cell expansion. For the homozygous CDK1-TK/CDK1-TK simulation, we initiated the batch 180 
production from an SU/SU cell, while for the heterozygous CDK1-TK/CDK1wt simulation, the initiating 181 
cell was SU/su1. Lastly, for the compound heterozygous CDK1-TK/CDK1null simulation, the initiating 182 
cell was SU/su2, since the su1 is functionally equivalent to CDK1wt, while su2 is the same 183 
as a CDK1null allele (Fig. 2a). 184 
A batch of cells is considered FS if it does not contain any escapees (Fig. 2d). The MC simulation 185 
determined the frequency of getting a non-FS batch of cells, which allowed us to calculate the FSL as the 186 
function of the cell number needed for a therapeutic cell batch. Fig. 2e shows these functions for the 187 
different initiating cell genotypes detailed above. 188 
The number of cells required for a cell therapy is disease-specific and is estimated to range between 189 
105 (i.e. eye31,32) and 1010 (i.e. heart33) cells. The genotype scenarios presented in Fig. 2e shows that a 190 
single TK insertion (CDK1-TK/CDK1wt, CDK1-TK/CDK1null) gives a low FSL for the cell numbers 191 
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required for therapy. Contrarily, a homozygous TK insertion into CDK1 significantly increases the 192 
FSL and brings the safety into a clinically relevant range for many future cell therapies. Diseases, such as 193 
arthritis, diabetes or myocardial infarction, however, require a larger number of therapeutic cells (108 to 194 
1010 donor cells). In this range, even the homozygous CDEL-SU provided FSL is insufficient (FSL<10). 195 
For this disease category, we propose the homozygous modification of two different CDELs with suicide 196 
genes. In this scenario, our MC simulation showed an enormous increase in FSL (FSL>106 for all 197 
clinically relevant batch volumes, Fig. 2e). 198 
We observed that the logarithm of FSL, as a function of the logarithm of the cell number, is a 199 
convex function. It is very close to a linear function when the FSL is above 10 and the cell number is in 200 
the clinically relevant range. Therefore, for an estimation of FSL, we applied linear regression to 201 
these segments (Fig. 2e).  Interestingly, the slope of the two linear regressions (Fig. 2e) is very close 202 
to minus one (-0.99) and the y-intercepts of these lines were close to 9 and 16 for one and two CDEL 203 
modifications, respectively. Using these approximates, the calculation of FSLs becomes 204 
very simple, while remaining the desired underestimates (Fig. 2e): 205 
 206 
For one CDEL: FSL = 109/cn, and for two CDELs: FSL = 1016/cn, where cn is the cell number needed for 207 
a therapeutic cell batch. 208 
 209 
Concerning the production of cells for a specific therapy, some are lost during differentiation or 210 
expansion. To account for this, the efficiency of cell production should be accurately estimated and the 211 
cell number needed to generate a therapeutic batch should be corrected accordingly. 212 
In future autologous cell therapies, the generation of multiple therapeutic batches might not be 213 
necessary, and a single FS clone could be grown up to the number of cells required for therapy. On the 214 
other hand, if allogeneic cells are desired or HLA haplobanks34 of human pluripotent cell lines will be 215 
operational, the generation of an off-the-shelf bank of cell batches  would be advantageous. In this 216 
scenario, it would be more practical and economical to produce a large pool of cells which, following 217 
quality control (QC) analysis, could be aliquoted into therapeutic doses. Consequently, we calculated the 218 
effect of aliquoting on FSL using both mathematical (Supplementary Calculation 1) and Monte-Carlo 219 
modeling approaches. On the basis of our established in silico model (Fig. 2e), we simulated the process 220 
of escapee accumulation until the final pool size reached 220 and 227 cells. In both of these scenarios, we 221 
calculated escapee generation frequency distributions. Next, we randomly picked A aliquots from these 222 
pools and calculated the mean number of “bad” aliquots (containing one or more escapee) in each case. 223 
By dividing the overall number of aliquots A by the number of bad aliquots, we calculated the aliquot FSL 224 
(FSLap). The ratio between FSLap and the FSL of the cell population size 220/A or 227/A (FSLa), is shown 225 
in Fig. 2f (red and orange lines, respectively). To confirm the results of this approach, we also calculated 226 
the same ratio using only theoretical assessment, where the final equation is as follows (Fig. 2f, blue line): 227 
 228 !"#$%!"#$ ≈ 1((1 − ∑ 2-.-/0-/.12 (( − 1( )45) 229 
 230 
The decrease in FSL is largest when a small number of aliquots are used (Fig. 2f, blue line). Within 231 
a practical range of aliquots (100-500), the FSL of the batches remains almost constant, with the 232 
probability modeling slightly underestimating the FSL drop. Consequently, aliquoting results in an 233 
approximately five-fold decrease in FSL using both approaches. The difference between aliquoting from 234 
a 220 (~106) vs. 227 (~ 109) pool shows that the drop is moderately larger (Fig. 2f) when we generate 235 
aliquots from a pool size that is close to the edge of the linear part on the original FSL graph (Fig. 2e). 236 
Following the generation of every cell batch or pool, a quality control (QC) needs to be performed 237 
to ensure that the originating cell was FS and consequently, the FSL calculation was correct. To 238 
where A is the number of aliquots generated from 
the pool of cells, and m is the integer part of the base 
2 log of the aliquot size. 
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demonstrate the practicality of the QC process, we grew several batches of cells from a single, 239 
homozygous FS ES cell. At the early phase of expansion, we verified that both CDK1-TK alleles were 240 
expressed and intact in the batch-originating single cell using flow cytometry and through allele-specific 241 
PCR (Extended Data Fig. 9) and sequencing of the TK-coding region. 242 
Both mouse and human ES cells with the homozygous modification of CDK1 have normal ES cell 243 
morphology and self-renewing capacity in standard ES cell culture conditions (Fig. 3a,b). The cells 244 
differentiated into the three embryonic germ layers in teratomas (Fig. 3c,d). Furthermore, we 245 
generated chimeric mice from the Cdk1-TK heterozygous mouse ES cells, and after germline 246 
transmission, obtained viable heterozygous and then homozygous adult mice (Fig. 3e, Extended Data Fig. 247 
6a). Homozygous FS H1 human ES cells express pluripotency markers (Fig. 3f), and were successfully 248 
differentiated into retinal pigmented epithelial (RPE) cells35 (Fig. 3g-i), adipocytes, osteocytes, 249 
chondrocytes (Fig. 3j), definitive endoderm (Fig. 3k), pharyngeal pouch endoderm36 (Fig. 3l) and beating 250 
cardiomyocytes (Supplementary Video 1). Additionally, using in vitro neural differentiation, we 251 
demonstrated the selective killing of dividing cells by the FS system. As expected, following a brief GCV 252 
treatment, all mitotically active cells were eliminated while non-diving cells were spared (Fig. 3m). This 253 
ability could represent a valuable safety measure prior to the transplantation of cells into a recipient. 254 
Although we previously demonstrated the robustness of the FS system using a breast cancer 255 
transplantation assay, we also wanted to simulate a clinical cell transplantation scenario gone awry. To 256 
accomplish this, we subretinally injected a 3:1 mixture of human homozygous FS RPE cells and human 257 
homozygous FS ES cells (mCherry tagged) into the eyes of NSG mice. Among 4 injected eyes, we did 258 
not observe any cell growth from the ES cell component of the graft when GCV was administered 24 259 
hours post-injection for a period of 28 days, as a preventative measure (Fig. 4a-b, Extended Data Fig. 10a-260 
c). In contrast, cell growth was detectable in 6 eyes that received an initial PBS treatment (Fig. 4c, 261 
Extended Data Fig. 10e-i). Importantly, even when GCV administration is delayed three weeks post-262 
injection and cell growth has already been detected, the homozygous FS system efficiently stopped the 263 
growing ES cell-derived component of the graft; only non-dividing cells remained (Fig. 4c, Extended Data 264 
Fig. 10g-i). This experiment illustrates the ability of the FS system to selectively eliminate proliferating 265 
cells after cell transplantation. Furthermore, neither the initial nor the delayed GCV treatment affected the 266 
RPE graft or the integrity of the surrounding retinal tissue (Fig. 4b,c, Extended Data Fig. 10). 267 
No therapy is without risk. Understanding and quantifying the risks associated with cell-based 268 
therapies is critical for the clinical advancement of regenerative medicine. Without a measurable safety 269 
system, it remains a challenging ambition to develop cell therapies that can treat degenerative diseases 270 
with an acceptable level of safety. We have developed a genome-editing strategy that allows a fundamental 271 
definition of safety, as well as a quantification of the safety level as a function of the cell number needed 272 
for any given cell therapy. 273 
After transcriptionally linking a cell suicide element to a cell division essential locus, we 274 
mathematically defined and quantified the safety of our FS system. These calculated risks are highly 275 
conservative, and represent an underestimate of the actual safety level of the system, as they were 276 
performed using worst-case scenarios. This is necessary because the cells required for therapies (100 277 
thousand to 10 billion) will need to be grown ex vivo. These conditions entail serious risks compared to 278 
most in vivo settings, where functional immune cells constantly surveil and eliminate transformed cells37. 279 
Additionally, since the number of cells needed will necessitate a similar number of genome duplications, 280 
any possible mutation could arise. Some mutations, such as a dominant negative heterozygous P53 can 281 
lead to a growth advantage38 that allows mutant cells to rapidly take over the entire population within a 282 
competitive culture environment. For these reasons, the safety of in vitro-generated therapeutic cells must 283 
be vigorously assessed. 284 
The concept and genome-editing approach presented here not only addresses these concerns, but 285 
also allows one to define cell therapy safety in a quantitative way. We contend that the risks, as determined 286 
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through experimentation and calculation, are sufficiently low and that the FS system will become an 287 
indispensable component of prospective cell therapies. Moreover, our approach to assess and quantify the 288 
safety of cell-based therapies will be critical for informed decision making by the regulators, clinicians 289 
and patients who will advance the therapies that will transform modern medicine. 290 
 291 
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 409 
Methods 410 
Generation of targeting vectors. Targeting vectors were generated by DNA synthesis, molecular 411 
cloning, recombineering and the NEBuilder HiFi DNA Assembly Cloning Kit (New England Biolabs). 412 
Generation of CRISPR/Cas9 vectors. pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng 413 
Zhang (Addgene plasmid # 42230)39. Guide sequences for CRISPR/Cas9 were analyzed using the 414 
online CRISPR design tool (http://crispr.mit.edu). Guide sequence for mouse Cdk1 targeting: 415 
TAAGAAGATGTAGCCCTC. Guide sequence for human CDK1 targeting: 416 
CTATCTGTTGACATAACATA. 417 
Mouse ES cell culture. C57BL/6N C2 ES cells were grown at 37°C in 95% air 5% CO2 on MEFs 418 
obtained from TgN(DR4)1Jae/J mice (http://jaxmice.jax.org/strain/003208.html) at all times except for 419 
one passage on gelatinized tissue culture plates prior to aggregation40. Two types of media were used: 420 
1). FBS-DMEM ES cell medium for gene targeting consisted of high glucose DMEM supplemented 421 
with 15% FBS (previously shown to support germline chimera generation), 2 mM GlutaMAX, 1 mM 422 
Na Pyruvate, 0.1 mM non-essential amino acids (NEAA), 50 U/ml penicillin and streptomycin (all 423 
Thermo Fisher Scientific), 0.1 mM 2-mercaptoethanol (Sigma) and 1000 U/ml LIF prepared with LIF 424 
producing plasmid.41 2). KOSR+2i medium was used for 2-4 passages prior to the generation of ES 425 
cell chimeras13. KOSR+2a consisted of high glucose DMEM medium supplemented with 15% 426 
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KnockOut Serum Replacement (KOSR) (Thermo Fisher Scientific), 1 mM Na Pyruvate, 0.1 mM 427 
NEAA, 0.1 mM 2-mercaptoethanol, 2 mM GlutaMAX , 50 U/ml penicillin/streptomycin, 500 U/ml 428 
LIF, 5 mg/ml Insulin (Thermo Fisher Scientific), 1 µΜ of the mitogen-activated protein kinase inhibitor 429 
PD0325901 (StemGent) and 3 µΜ of the glycogen synthase kinase-3 inhibitor CHIR99021 430 
(StemGent). Cells were fed daily and passaged when they reached a confluency of 70-80%. 0.05% 431 
Trypsin-EDTA (Thermo Fisher Scientific) was used for the passage of cells grown in FBS-DMEM and 432 
Accutase (STEMCELL Technologies) was used for cells grown in KOSR+2i medium. 433 
Mouse ES cell targeting. 50,000 mouse C57BL/6N C2 ES cells were transfected with 2 µg DNA 434 
(Mouse Target Vector 1 or 2: 1.5 µg, CRISPR vector: 0.5 µg) by JetPrime transfection (Polyplus). The 435 
cells were selected for G418-resistance (160 µg/ml) starting 48h after transfection. Resistant clones 436 
were picked independently and replicated in 96-well plates for freezing and genotyping with PCRs. 437 
PCR-positive clones were expanded, frozen to multiple vials, and genotyped by Southern blotting. 438 
Selection cassette excision in mouse ES cells. Correctly targeted ES cell clones were transfected with 439 
episomal-hyPBase (for Mouse Target Vector I) or pCAGGs-NLS-Cre-IRES-puromycin (for Mouse 440 
Target Vector II). 2-3 days following transfection, cells were trypsinized and plated clonally (1,000 - 441 
2,000 cells per 10 cm plate). mCherry-positive clones were picked and transferred to 96-well plates 442 
independently and genotyped by PCR and Southern blotting to confirm the excision event. The 443 
junctions of the removal region were PCR-amplified, sequenced, and confirmed to be intact and 444 
without any frameshift mutations. GCV (Sigma) to test for TK activity was used at a final concentration 445 
of 1 µM. 446 
Human ES cell culture. Human CA1 and H1 ES cells were cultured on Geltrex (Thermo Fisher 447 
Scientific) using mTeSR1 media (STEMCELL Technologies) containing 50 U/ml 448 
penicillin/streptomycin (Thermo Fisher Scientific). Cells were passaged using TryplE Express 449 
(Thermo Fisher Scientific) and were subsequently plated in mTeSR media containing 10 µM ROCK 450 
inhibitor (Selleckchem) for 24 hours. 451 
Human ES cell targeting. For Human Targeting Vectors I & II, 6 million human ES cells were 452 
electroporated using Neon Transfection System (Thermo Fisher Scientific) with protocol 14 (pulse 453 
voltage: 1200 mV, pulse width: 20 ms, pulse number: 2) with 24 µg DNA (Target Vector: 18 µg, 454 
CRISPR vector: 6 µg). After transfection, cells were plated on four 10 cm plates. G418 selection at 30 455 
µg/ml or puromycin selection at 0.75 µg/ml was initiated 48h after transfection. Independent colonies 456 
were picked to 96-well plates and each plate was duplicated for further growth and genotyping with 457 
PCR. PCR-positive clones were expanded, frozen to multiple vials, and genotyped with Southern 458 
blotting. For Human Target Vector III targeting, 10 million human ES cells were electroporated using 459 
Neon protocol 14 with 40 µg DNA (Human Target Vector III: 30 µg, CRISPR vector: 10 µg), and 460 
plated in four 10 cm plates. 3-4 days after transfection, cells that were double-positive for mCherry and 461 
eGFP were sorted into one well of a 96-well plate. After recovery from FACS, cells were dissociated 462 
and plated clonally (1,000 - 2,000 cells per 10 cm plate). Next, clones were picked independently, 463 
replicated, and transferred to 96-well plates for freezing and genotyping with PCR. PCR-positive 464 
clones were expanded, frozen to multiple vials, and genotyped by Southern blotting. 465 
Selection cassette excision in human ES cells. 1 million correctly targeted ES cell clones were 466 
electroporated with 2 µg episomal-hyPBase-IRES-puro (for Human Target Vector I) or 2 µg episomal-467 
Cre-IRES-puro (for Human Target Vector II) using Neon protocol 14. Once the cells were confluent 468 
in 6-well plates, mCherry-positive cells were sorted to one well of a 96-well plate by FACS. After 469 
recovery, cells were dissociated and plated clonally (1,000 - 2,000 cells per 10 cm plate). Clones were 470 
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picked and transferred to 96-well plates independently and genotyped by PCR and Southern blotting 471 
to confirm the excision event. The junctions of the removal region were PCR-amplified, sequenced 472 
and confirmed to be intact and without frameshift mutations. 473 
PCR genotyping. 2X Taq PCR master mix (Biomart) was used for all PCR reactions. Genomic DNA 474 
from human cell pellets was extracted using the DNeasy Blood & Tissue Kit (Qiagen). The primer 475 
pairs and conditions used for each reaction are listed in Supplementary Table 2. 476 
Southern blotting. 10 µg of genomic DNA was extracted from PCR-positive clones, digested with 477 
ScaI-HF overnight, resolved by 0.6 - 0.7% gel electrophoresis, and transferred to Hybond N+ (GE 478 
Healthcare). The following probes were labelled with 32P and used to hybridize with the membrane 479 
(~25 ng probe per ml hybridization solution). Human CDK1 genomic probe: PCR amplified with 480 
primers hCDK1-Probe6-F + hCDK1-Probe6-R. Mouse Cdk1 genomic probe: PCR amplified with 481 
primers 647302FWD + 647302REV. mCherry probe: the entire length of mCherry. eGFP probe: the 482 
entire length of eGFP. TK-mCherry probe: cut from hCDK1-PB-neo-TK-mCherry with 483 
Bsu36I+SgrAI: 1092 bp, gel-purified. 484 
Mice. The CD-1 (ICR) (Charles River) outbred albino stock was used as embryo donors for aggregation 485 
with ES cells and as pseudopregnant recipients. C57BL/6NCrl (Charles River) was used as the host for 486 
teratoma assays with mouse C2 ES cells. C57BL/6NCrl or B6N-Tyr_c N4/Crl#493 (Charles River) 487 
was used as the host for mammary fat pad transplantation of mammary epithelial cells. NOD scid 488 
gamma /J#5557 (Jackson Laboratories) was used as the host for teratoma assays with human H1 or 489 
CA1 ES cells. FVB/N-Tg(MMTV-PyVT)634Mul/J was a gift from Dr. William Muller’s lab20, and the 490 
backcross to B6J background was done by Dr. Anthony Pawson’s lab. Animals were maintained on a 491 
12 h light/dark cycle and provided with food and water ad libitum in individually ventilated units 492 
(Techniplast) in the specific-pathogen free facility at The Centre for Phenogenomics (TCP). All 493 
procedures involving animals were performed in compliance with the Animals for Research Act of 494 
Ontario and the Guidelines of the Canadian Council on Animal Care. 495 
Generation of chimeras and mouse lines. Morula aggregations were performed as previously 496 
described40. Chimeras were identified at birth by the presence of black eyes and later by coat 497 
pigmentation. Male chimeras with more than 50% ES cell contribution to coat colour were bred with 498 
CD-1 females to identify germline transmitter. The transmitter was then bred with C57BL/6NCrl 499 
females and pups were confirmed by genotyping to obtain Cdk1-TK/Cdk1 mice. Cdk1-TK/Cdk1 500 
MMTV-PyMT males were generated by breeding MMTV-PyMT (B6) males and Cdk1-TK/Cdk1 501 
females. Cdk1-TK/Cdk1; MMTV-PyMT and Cdk1-TK/Cdk1-TK; MMTV-PyMT female mice were 502 
generated by breeding Cdk1-TK/Cdk1; MMTV-PyMT males and Cdk1-TK/Cdk1 females. 503 
Teratoma assay. Matrigel Matrix High Concentration (Corning) was diluted 1:3 with cold DMEM 504 
media on ice. 1-5 million mouse ES cells or 5-10 million human ES cells were suspended in 100 µl of 505 
Matrigel-DMEM and injected subcutaneously into one or both dorsal flanks of C57BL/6NCrl mice 506 
(for mouse C2 ES cells) and NOD scid gamma /J#5557 mice (for human H1 and CA1 ES cells). 507 
Teratomas formed 2-4 weeks after injection. Teratoma size was measured using calipers and volume 508 
was calculated using the formula V= (LxWxH)π/6. GCV /PBS treatment was performed through daily 509 
intraperitoneal injections (50 mg/kg) with varying treatment durations. At the end of treatment, mice 510 
were sacrificed and tumors were dissected and fixed in 4% paraformaldehyde for histological analysis. 511 
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Breast cancer transplantation assay. Cdk1-TK/Cdk1; MMTV-PyMT and Cdk1-TK/Cdk1-TK; 512 
MMTV-PyMT female mice developed mammary gland tumours between 3-6 months old. Mammary 513 
epithelial tumorigenic cells were isolated from developed tumours through digestion in 10× 514 
collagenase/hyaluronidase (STEMCELL Technologies),  and dilution to 1x with media consisting of 515 
DMEM/F12 (Thermo Fisher Scientific) + 10% FBS + 50 U/ml penicillin/streptomycin for an hour in 516 
37 degree. The digested cells were washed and pelleted with DMEM/F12 + 10% FBS 4 times, and 517 
plated in CnT-PRIME epithelium culture media (CELLnTEC Advanced Cell Systems AG) on plates 518 
coated with 0.1% gelatin (Sigma). Without passaging, primary mammary epithelial cells were 519 
dissociated and re-suspended in PBS at 10,000 cells per µl, and 50 µl (500,000 cells) was transplanted 520 
to each mouse by intraductal injection after making a small abdominal skin incision as previously 521 
described42. Tumour measurement and PBS/GCV treatment were the same as described in the teratoma 522 
assay. 523 
Differentiation of human ES cells into retinal pigmented epithelial (RPE) cells. RPE differentiation 524 
was performed as previously described35 with minor changes. Human ES cells were plated on Geltrex-525 
coated 6-well plates and cultured in feeder-free conditions with mTeSR medium until confluency was 526 
reached and the colonies lost their tight borders (7-10 days). Next, the media was replaced with 527 
differentiation media (basal media with 13% KOSR) and changed every 2-3 days. The basal media 528 
consisted of KO-DMEM supplemented with 50 U/ml penicillin/streptomycin mix, 1 mM Na Pyruvate, 529 
0.1 mM NEAA, 2 mM of GlutaMAX and 0.1 mM 2-mercaptoethanol. Initial pigmentation was 530 
observed approximately 3 weeks after the switch to differentiation media. Clusters of RPE cells were 531 
manually picked and transferred to a Geltrex-coated 24-well plate (3 clusters/well) when they were 532 
large enough (~1mm in diameter) for enrichment and the media was changed to RPE media, consisting 533 
of basal media with 5% FBS, 7% KSR and 10 ng/ml bFGF (Peprotech). 534 
Differentiation of human ES cells into definitive endoderm. Definitive endoderm differentiation 535 
was performed using the STEMdiff Trilineage Differentiation Kit (StemCell Technologies), and 536 
characterized by immunostaining for SOX17 and FOXA2 (Supplementary Table 3). 537 
Differentiation of human ES cells into pharyngeal pouch endoderm (PPE). PPE differentiation 538 
was performed as previously described36 with the only modification being that the induction from ES 539 
cells to definitive endoderm is one day shorter than reported. 540 
Differentiation of human ES cells into mesenchymal stem cells (MSCs) and subsequent 541 
adipogenic, osteogenic and chondrogenic differentiation. ES cells were cultured in mTeSR medium 542 
for 2 days. Next, cells were induced into early mesoderm progenitor cells with STEMdiff Mesenchymal 543 
Induction Medium (STEMCELL Technologies) for 4 days and then were maintained with MesenCult-544 
ACF Medium (STEMCELL Technologies). Cells were continually passaged onto 6-well plates pre-545 
coated with MesenCult-ACF Attachment Substrate (STEMCELL Technologies) to derive early 546 
mesenchymal progenitor cells. At day 21, the MSCs showed a fibroblast-like morphology and the 547 
culture medium was changed every 3 days. For adipogenic differentiation, MSCs at a density of 20,000 548 
cells/well were plated with MesenCult-ACF Attachment Substrate and cultured with MesenCult-ACF 549 
Medium for 2 days. Adipogenesis was induced using the StemPro Adipogenesis Differentiation Kit 550 
(Thermo Fisher Scientific). After 21 days, lipid droplets were visualized using Oil Red O (Sigma). For 551 
osteogenic differentiation, ES-derived MSCs at the density of 50,000 cells/well were plated with 552 
MesenCult-ACF Attachment Substrate and cultured with MesenCult-ACF Medium for 2 days. 553 
Osteogenesis was induced using the StemPro Osteogenesis Differentiation Kit (Thermo Fisher 554 
Scientific). After 21 days, calcium deposition was visualized using Alizarin Red (Sigma). For induction 555 
of chondrogenic differentiation, ES-derived MSCs were centrifuged in 15 ml conical tubes at 500g for 556 
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5 mins to create cell pellets with 5,000,000 cells per pellet. Chondrogenesis was induced using the 557 
StemPro Chondrogenesis Differentiation Kit (Thermo Fisher Scientific). After 21 days, cartilage was 558 
visualized using Alcian Blue (Sigma). Differentiation media was changed every 3 days. 559 
Differentiation of human ES cells into beating cardiomyocytes. Cardiomyocyte differentiation was 560 
performed using STEMdiff Cardiomyocyte Differentiation Kit (STEMCELL Technologies). 561 
Differentiation of human ES cells into neuronal progenitors and neurons. To differentiate human 562 
ES cells into neuronal progenitors, human ES cells were plated at 50-100,000 cells per cm2 in 1:1 563 
DMEM/F12 : Neurobasal (Thermo Fisher Scientific), 0.5x N2 supplement (home-made, 1.92 mg/ml 564 
putrescine, 2.376 µg/mL progesterone, 3.6 µM Selenium, 10 mg/mL Apo-transferrin, 0.75% BSA, 20 565 
g/ml insulin), 0.5x B27 supplement with Vitamin A (Thermo Fisher Scientific), 2 mM Glutamax, 0.1 566 
mM Beta-mercaptoethanol, 50 U/ml penicillin/streptomycin, 10 µM SB431542 (Selleckchem), 100 567 
nM LDN193189 (Selleckchem) (+10 µM ROCK inhibitor overnight only, then removed). Cells were 568 
maintained in this condition for 8 days and media was changed every other day. Next, neuronal 569 
progenitors were dissociated with Accutase and plated at a density of 5x104 cells per cm2 on laminin 570 
(Sigma, 1 µl for 1cm2, diluted in 250 µl PBS without Ca and Mg) in fast neuron differentiation media, 571 
1:1 DMEM-F12: Neurobasal, 1x B27 supplement with Vitamin A, 5 µM DAPT (Selleckchem), 2 mM 572 
Glutamax, 0.1 mM Beta-mercaptoethanol, 50 U/ml penicillin/streptomycin. Media were changed every 573 
three days. 10 µM GCV was added 6 days after neuron differentiation and kept for 6 days. 10 µM BrdU 574 
(Sigma) was added after 5 days of GCV treatment and the cultures were fixed after 6 days of GCV 575 
treatment and were immunostained for BrdU and beta-TublinIII (Supplementary Table 3). 576 
Flow cytometry analysis and fluorescence-activated cell sorting (FACS). Flow cytometry and 577 
FACS were both performed and analyzed by the Lunenfeld-Tanenbaum Research Institute flow 578 
cytometry facility. FACS was performed using the ASTRIOS EQ cell sorter. Flow cytometry was 579 
performed using the GALLIOS flow cytometer and evaluated using Kaluza Analysis Software 580 
(Beckman Coulter). Samples were gated for live single cells using forward scatter, side scatter and 581 
DAPI staining. Wild-type and single-color samples of the same cell type as the experimental samples 582 
were used for negative controls and compensation calculations. Human ES cell samples were single-583 
cell sorted using StemFlex Medium (Thermo Fisher Scientific) plus 10 µM ROCK inhibitor. 584 
Immunostaining. 4% PFA-fixed cells were blocked and permeabilized with 5% goat serum + 1M 585 
Glycine + 1% Triton X-100 (all Sigma) in PBS without Ca and Mg or animal-free blocker (Vector 586 
Laboratories) + 1% Triton X-100 in milliQ water. All of the primary antibody information can be found 587 
in Supplementary Table 3. Staining was visualized using a Zeiss LSM780 confocal microscope. 588 
Histology analysis. Paraffin embedding, paraffin block sectioning, and H&E staining were performed 589 
by the Pathology Core of The Centre for Phenogenomics. 590 
Quantitative PCR. Gene expression analyses were completed as follows: RNA extraction by 591 
GenElute™ Mammalian Total RNA Miniprep Kit (Sigma), reverse transcription with QuantiTect 592 
Reverse Transcription Kit (Qiagen), Q-PCR with SensiFAST SYBR No-Rox Kit (Bioline) on Bio-Rad 593 
CFX Real-Time Systems (Bio-Rad), and analysis with Bio-Rad CFX Manager 3.1. All the information 594 
of primers and probes for the TaqMan Q-PCRs can be found in Supplementary Table 2. The reactions 595 
were performed using TaqMan Genotyping Master Mix (Thermo Fisher Scientific) and CFX Real-596 
Time Systems, and were analyzed by CopyCaller Software v2.1 (Thermo Fisher Scientific). 597 
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Luria and Delbruck assay. The Luria and Delbruck assay was performed as previously described22. 598 
CDK1-TK homozygous 3C cells were single-cell plated in a 96-well plate using FACS. 21 single cell-599 
derived cultures were grown to an average of 5 million cells per culture, and the number of single-600 
positive cells in each culture were analyzed using flow cytometry. The mutation rate was calculated 601 
using the previously described equation23 in https://www.wolframalpha.com/. 602 
In vivo transplantation of RPEs. CDK1-TK homozygous 3C ES cells were transfected with PB-603 
CAGGs-mCherry-pA plasmid and sorted for high expressors. 40,000 3C-derived RPEs only or 30,000 604 
3C-RPEs plus 10,000 mCherry-tagged 3C ES cells were injected subretinally with 0.5%/0.5% (wt/vol) 605 
hydrogel blend of hyaluronan and methylcellulose (HAMC) in HBSS. PBS or GCV (50 mg/kg) 606 
treatment were started the day after cell injection and were given every other day through 607 
intraperitoneal injections. Monitoring by fundoscopy and optical coherence tomography were 608 
performed on the day after transplantation and then once a week. 609 
Monte Carlo simulation. An ES cell population was considered as a mix of mutant and non-mutant 610 
cells with reference to the CDEL-SU locus (or loci). All possible mutations were categorized into three 611 
different types: type 1, when only the SU part of the locus becomes non-functional (su1 allele); type 2, 612 
when both the CDEL and SU become non-functional (su2 allele); type 3, when any of the above occurs 613 
as a result of LOH (Fig. 2a,b). Back mutations, such as su1—>SU or su2—>SU or su2—>su1, were 614 
not considered, due to their extremely low probabilities (Fig. 2c). Back mutations, like SU/su1 -> 615 
SU/SU, SU/su2 -> SU/SU and su1/su2 -> su1/su1, were considered as a part of the more frequent LOH 616 
process. p1, p2, and p3 were designated the probabilities of each mutation type, respectively. We 617 
distinguished between two types of p3: p3mr (probability LOH occurred through mitotic 618 
recombination), where both daughter cells survive; and p3cnd (probability LOH occurred through 619 
chromosomal non-disjunction), where one of the daughter cells with the single remaining copy of the 620 
chromosome is likely to die43. On the basis of these probabilities, matrices of transitions between all 621 
possible genotypes within one or two CDEL systems were constructed (Fig. 2c, 622 
https://github.com/mashutova/failsafe). 623 
         With each division cycle (d), all cells within the population except cells with the su2/su2 624 
genotype, were allowed to divide. Genotypes of su1/su2 and su1/su1 were considered escapees and the 625 
simulation initiated from one non-mutant cell. N(g1,d) was the number of cells of genotype g1 at 626 
doubling d, and p(g1,g2) was the probability of transition from genotype g1 to g2. In each doubling the 627 
number of cells changing genotype from g1 to g2 was determined through random sampling from a 628 
binomial distribution with parameters 2*N(g1,d-1) and p(g1,g2). We used Poisson approximation of 629 
binomial distribution to work with ultra-low p(g1,g2). For each division, the number of cells of each 630 
genotype was assessed, and the simulation proceeded until the first escapee was detected. 631 
         For each starting genotype, we performed more than 10 million simulations and obtained a 632 
distribution of the number of doublings from the detection of the first escapee. On the basis of this data, 633 
we generated a function of FSL (overall number of trials divided by number of trials with escapees) 634 
over cell population size (2^d) (Fig. 2d). Since all graphs contain almost linear regions, we used linear 635 
models to extrapolate them to high FSL values. To obtain linear regression lines, we only used 636 
simulated points from the linear-like part of the graph (R-squared > 0.999) with 95% confidence 637 
intervals less than 1000. To obtain a conservative boundary for the FSL, we used only the lowest CI 638 
values to build linear regressions. 639 
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To analyse the outcome from the aliquoting of the pool of fail-safe cells possibly containing 640 
escapees, using probability modelling we developed the following formula to calculate the drop of FSL 641 
(for details see Supplementary Calculation 1) 642 !"#$%!"#$ ≈ 1((1 − ∑ 2-.-/0-/.12 (( − 1( )45) 643 
To reduce the complexity of the model, we considered only one escapee event in the pool, as 644 
the possibility of two independent escapees occurring in a pool is low in the quasi linear phase of FSL. 645 
Nevertheless, we tested the effect of this omission on the drop of FSL due to aliquoting using Monte 646 
Carlo simulation. We performed 10 million independent trials for a doubling of 20 and a doubling of 647 
27, and obtained a distribution of the number of escapees for each of them. Through randomly sampling 648 
a number of escapees from each trial to the A aliquots, we calculated the number of “bad” aliquots 649 
containing one or more escapees (Ab). To calculate a new FSL of the population after aliquoting, where 650 
FSLp is the FSL of the original population, we used the formula A*FSLp/mean(Ab). The drop in FSL 651 
was measured in silico and was compared with the one we obtained from the equation obtained from 652 
the probability model. 653 
Data availability. The DNA sequences of the vectors and plasmids used in this study are available 654 
upon request. 655 
 656 
 657 
39. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science 339, 819–658 
823 (2013). 659 
40. Behringer, R., Gertsenstein, M., Nagy, K. V. & Nagy, A. Manipulating the Mouse Embryo. 660 
(2013). 661 
41. Mereau, A., Grey, L., Piquet-Pellorce, C. & Heath, J. K. Characterization of a binding protein for 662 
leukemia inhibitory factor localized in extracellular matrix. The Journal of Cell Biology 122, 713–663 
719 (1993). 664 
42. Park, J., Kusminski, C. M., Chua, S. C. & Scherer, P. E. Leptin Receptor Signaling Supports 665 
Cancer Cell Metabolism through Suppression of Mitochondrial Respiration in Vivo. The 666 
American Journal of Pathology 177, 3133–3144 (2010). 667 
43. Biancotti, J.-C. et al. The in vitro survival of human monosomies and trisomies as embryonic 668 
stem cells. Stem Cell Research 9, 218–224 (2012). 669 
 670 
  671 
16 
 
 672 
 673 
Figure 1 | Fail-safe cell system: the concept, the definition, realization and properties. a, The 674 
suicide gene is placed into a cell division essential locus (CDEL) resulting in a bicistronic mRNA that is 675 
translated into two proteins; a cell division essential factor and a drug-inducible suicide factor. b, Visual 676 
17 
 
representation of the fail-safe level (FSL) defined by one non-fail-safe batch out of how many batches. 677 
c, The link between the prototype SU (HSV-TK) and the prototype CDEL (CDK1). d, Representative 678 
growth of teratomas formed by mouse Cdk1-TK/Cdk1 cells, when the recipients were treated with PBS 679 
or GCV. e, Adult mouse with stabilized subcutaneous tissue (fail-safe ES cell-derived dormant teratoma) 680 
2.5 months after GCV treatment. f, Representative growth of teratomas formed by human CDK1-681 
TK/CDK1 ES cells, when the recipients were treated with PBS or GCV. g, Representative growth of 682 
teratomas formed by mouse Cdk1-TK/Cdk1-TK ES cells. h, Representative growth of teratomas formed 683 
by human CDK1-TK/CDK1-TK ES cells i, Copy number analysis of mouse Cdk1-TK/Cdk1 escapees 684 
identified in the experiment described in Extended Data Fig. 7.  685 
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Figure 2 | Modelling the FS cell system and calculating FSL. a, Three types of mutations that could 687 
affect the CDEL-SU allele. b, FS allele transition considered in the modelling and MC simulations. c, 688 
Genotype transition matrix considered in the modelling and MC simulations. d, Visual illustration of FS 689 
and non-FS batch formation during cell expansion. e, The function between therapeutic cell number and 690 
FSL determined by MC simulation (data points) for different initiating cell genotypes. Solid lines show the 691 
approximated linear regression on the “close to linear” part of the functions. The bars on certain data points 692 
represent the 95% confidence intervals of the FSL estimates. f, The drop of FSL due to aliquoting from a 693 
pool of cells relative to non-aliquoted batches of the same size. 	694 
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Figure 3 | Mouse and human fail-safe homozygous CDK1-TK/CDK1-TK cells demonstrate 696 
pluripotency. All experiments were performed using the same clone of mouse C2 or human H1 (Exc16-697 
3C) CDK1-TK/CDK1-TK cells. a, Bright-field photograph showing mouse homozygous Cdk1-698 
TK/Cdk1-TK ES cell morphology. b, Bright-field photograph showing human homozygous CDK1-699 
TK/CDK1-TK ES cell morphology.  c, H&E staining of a mouse Cdk1-TK/Cdk1-TK ES cell derived 700 
teratoma. d, H&E staining of a human CDK1-TK/CDK1-TK ES cell derived teratoma. e, An adult Cdk1-701 
TK/Cdk1-TK mouse. f, OCT4 and NANOG staining of human CDK1-TK/CDK1-TK ES cells. g, Q-PCR 702 
characterization of CDK1-TK/CDK1-TK ES cell differentiation into RPE cells. Values represent mean ± 703 
SD, n = 3. h, Bright-field picture of human CDK1-TK/CDK1-TK ES cell derived RPE cells. i, ZO1 704 
staining of human CDK1-TK/CDK1-TK ES cell derived RPE cells. j, Human CDK1-TK/CDK1-TK ES 705 
cell derived adipocytes, chondrocytes and osteocytes. k, SOX17 and FOXA2 staining of human CDK1-706 
TK/CDK1-TK ES cell derived definitive endoderm. l, OCT4, NANOG, SOX17, FOXA2 and HOXA3 Q-707 
PCR characterization of ES cell (Day 0) differentiation into definitive endoderm (Day 4) and pharyngeal 708 
pouch endoderm (Day 8). Values represent mean ± SD, n = 3. m, Human CDK1-TK/CDK1-TK ES cell 709 
differentiation into neural epithelial progenitors and subsequent neurons, with or without GCV 710 
treatment. Scale bar 100 µm.  711 
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Figure 4 | Fail-safe cell system in action; an in vivo proof of principle study. a, A 3:1 mixture of 713 
human homozygous FS ES cell-derived RPE cells and homozygous FS ES cells were subretinally co-714 
injected into NSG mice and imaged using fundoscopy and optical coherence tomography (OCT) 715 
throughout GCV or PBS treatment. b, Fundoscopy, OCT and fluorescence imaging of the eye receiving 716 
GCV treatment (4 weeks). c, Fundoscopy, OCT and fluorescence imaging of the eye of the mouse that 717 
received PBS treatment (3 weeks) and developed an actively growing ES cell-derived lesion (mCherry+ 718 
cells). dpi stands for days post injection.   719 
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 720 
 721 
Extended Data Figure 1 | Schematic of targeting vectors for mouse and human CDK1. a, e, The 722 
genomic locus and structure of the mouse (a) and human (e) CDK1 gene. b, f, CRISPR/Cas9 target site for 723 
mouse (b) and human (f) CDK1. c, d, g, h, i, The targeting vectors used in the study.  The knock-in 724 
insertion replaced the CDK1 stop codon with an F2A sequence, followed by the TK.007 linked to a 725 
fluorescent protein gene with a T2A sequence. Adding fluorescent reporters (mCherry and eGFP) to the 726 
insert permitted the visualisation of the modified CDK1 allele expression in the cells. A positive selectable 727 
marker (neomycin or puromycin) was used to select for integration, and was subsequently removed by 728 
transiently expressing Cre recombinase or piggyBac (PB) transposase in the targeted cells, depending on 729 
the flanking loxP or PB terminal repeats (TR) in the target vector type, respectively. UTR: untranslated 730 
region, HA: homology arm, PGK: phosphoglycerate kinase, eGFP: enhanced green fluorescent protein, 731 
mCherry: mCherry fluorescent protein, pA: polyadenylation, Neo: neomycin selectable marker, Puro: 732 
puromycin selectable marker. 	733 
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 734 
 735 
Extended Data Figure 2 | Generation, genotyping and characterization of mouse C57BL/6N C2 736 
Cdk1-TK/Cdk1 and Cdk1-TK/Cdk1-TK ES cells. a, Summary of the targeting steps used to generate 737 
26 
 
mouse C2 Cdk1-TK/Cdk1 and Cdk1-TK/Cdk1-TK ES cells. b, Southern blot genotyping with internal 738 
TK-mCherry probe. c, Southern blot genotyping with mouse Cdk1 genomic probe. d, In vitro GCV 739 
dose-response killing curve of mouse C2 Cdk1-TK/Cdk1 ES cells. e, Teratoma formation efficiency of 740 
mouse C2 Cdk1-PB-TK/Cdk1, Cdk1-TK/Cdk1 and Cdk1-TK/Cdk1-TK ES cells.  741 
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28 
 
Extended Data Figure 3 | Generation, genotyping and characterization of human H1 CDK1-743 
TK/CDK1 and CDK1-TK/CDK1-TK ES cells. a, Steps of generating human H1 CDK1-TK/CDK1 and 744 
CDK1-TK/CDK1-TK ES cells. b, Southern blot genotyping of the CDK1-TK/CDK1 clone Exc16 used 745 
in teratoma assays (Fig. 1c and Extended Data Fig. 7) and the CDK1-TK/CDK1-TK clone Exc16-3C 746 
used in the differentiation assays in Fig. 3. c, PCR genotyping of all the correct clones. d, Flow 747 
cytometry analysis of the CDK1-TK/CDK1 clone Exc16 and the CDK1-TK/CDK1-TK clone Exc16-3C. 748 
e, SybrGreen Q-PCR of human CDK1 expression in H1 WT, the CDK1-TK/CDK1 clone Exc16 and the 749 
CDK1-TK/CDK1-TK clone Exc16-3C. Values represent mean ± SD, n = 3. No significant difference 750 
among them. f, TaqMan Q-PCR copy number analysis of TKs of all the clones with the correct 751 
genotype. g, Table showing the efficiency of teratoma formation in NSG mice using H1 human ES cells. 752 
h, Dose-response analysis of wild type, CDK1-TK/CDK1 and CDK1-TK/CDK1-TK human H1 ES cells. 753 
Cells were treated with different GCV concentrations, dissociated and counted after 7 days.  754 
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30 
 
Extended Data Figure 4 | Generation, genotyping and characterization of human CA1 CDK1-756 
TK/CDK1 and CDK1-TK/CDK1-TK ES cells. a, Steps of generating human CA1 CDK1-TK/CDK1 757 
and CDK1-TK/CDK1-TK ES cells. b, Southern blot genotyping of human CA1 CDK1-TK/CDK1 and 758 
CDK1-TK/CDK1-TK ES cells. The plasmid concatemers are multiple copies of plasmid integration 759 
(including backbone). The Ampicillin gene in the backbone contains a ScaI restriction enzyme site 760 
which is consistent with the sizes of the band in southern blots.  c, H&E staining of  a CDK1-TK/CDK1-761 
TK CA1 ES cell derived teratoma.  762 
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 764 
 765 
Extended Data Figure 5 | Growth graphs of mouse and human ES cells-derived teratomas. a, 766 
Growth of teratomas derived from mouse heterozygous fail-safe ES cells (C2 Cdk1-TK/Cdk1)   b, 767 
Growth of teratomas derived from mouse homozygous fail-safe ES cells (C2 Cdk1-TK/Cdk1-TK) c, 768 
Growth of teratomas derived from human heterozygous fail-safe ES cells (H1 CDK1-TK/CDK1, clone 769 
Exc16), daily GCV treatment. d, Examples of teratomas from human heterozygous fail-safe ES cells 770 
33 
 
showing cyst formation, images of cystic teratomas at dissection are shown next to the corresponding 771 
growth line, daily GCV treatment. The graphs with two lines represent mice that had cells injected to 772 
both flanks. The graphs with one line represent mice that had cells injected to one flank. The GCV 773 
treatment regime varies among mice because each teratoma behaves differently; we started GCV when 774 
the teratoma size started to increase. e, Growth of teratomas derived from human homozygous fail-safe 775 
ES cells (H1 CDK1-TK/CDK1-TK), GCV treatment was every other day. Images of cystic teratomas are 776 
shown next to the corresponding growth line, cysts were drained after dissection to show the difference 777 
in tumour weight due to the fluid present in the tissue. Each graph represents one mouse.   778 
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 779 
 780 
Extended Data Figure 6 | Breast cancer transplantation assay using heterozygous and homozygous 781 
FS mammary tumour cells. a, Generation of mouse line and experimental design. b, Growth of 782 
mammary gland tumours derived from mouse Cdk1/Cdk1 and Cdk1-TK/Cdk1 mammary epithelial cells 783 
with PBS or GCV treatment. c, Growth of mammary gland tumours derived from mouse Cdk1-TK/Cdk1-784 
TK mammary epithelial cells with PBS or GCV treatment. 	785 
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 787 
Extended Data Figure 7 | In vitro experiments with mouse C2 Cdk1-TK/Cdk1, Cdk1-TK/Cdk1-TK ES 788 
cells and subsequent characterization of escapees. a, Experimental design: mCherry+ cells were 789 
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selected by sorting to ensure that the starting cell population did not contain escapees. These cells were 790 
plated on 6 well plates (200 cells/well, 36 total wells) and allowed to grow to 14 cell doublings (this was 791 
estimated by counting cells in sample wells). The 36 cultures were then resuspended to a single-cell 792 
suspension and each was plated to a 15 cm plate (4x106 cells). One day after plating, selection with GCV 793 
was started and maintained until escapee colonies appeared. b, Escapee numbers obtained in 36 794 
independent cultures growing from Cdk1-TK/Cdk1, Cdk1-TK/Cdk1-TK ES cells. c, PCR to determine the 795 
presence of TK. d, TaqMan copy number Q-PCR analysis of Akap, Sim1, Cdk1 junction of exon 8 and 796 
3’UTR, Neurod, Cdk1, TK, Abca on mouse Chr. 10. Values represent the copy number calculated by 797 
CopyCaller Software v2.1 and the bars indicate the range from the minimum to the maximum number. n = 798 
3. The same color in the background of c and d indicates that they are from the same independent culture. 799 
e, Q-PCR to compare TK expression level in Cdk1-TK/Cdk1 escapee clone 2A and C2 WT ES cells. 800 
Values represent mean ± SEM. n = 3. 	801 
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 803 
Extended Data Figure 8 | Calculation of the LOH rate at the human CDK1 locus with human H1 804 
CDK1-TK/CDK1-TK ES cells. a, Summary table. b, Detailed cell number  for each individual clone. 	805 
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 806 
Extended Data Figure 9 | Quality control (QC) of batches generated from single human H1 CDK1-807 
TK/CDK1-TK ES cells. a, Schematics of the alleles in the CDK1-TK/CDK1-TK human ES cells used 808 
in the quality control. b, Workflow schematic of performing QC on several ES cell batches. c, An 809 
example of the flow cytometry for the QC of nine clonally derived batches. d, An example of PCR for 810 
the QC of nine clonally derived batches.  811 
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 824 
 825 
Extended Data Figure 10 | Images of all eyes co-transplanted with FS-RPE and FS-ES cells (in 826 
addition to Fig. 4), and images of all the eyes transplanted only with FS-RPE cells. a-c, 827 
Fundoscopy, OCT and fluorescence imaging of eyes co-transplanted with FS-RPE and FS-ES cells (4-828 
week GCV treatment). The absence of mCherry signal indicates that ES cell growth has not occurred. 829 
The bottom panel in c includes the green fluorescence channel to illustrate that the observed signal in the 830 
red fluorescence channel is actually autofluorescence. d, Histological analysis of the eye presented in e. 831 
e-i, Fundoscopy, OCT and fluorescence imaging of eyes co-transplanted with FS-RPE and FS-ES cells 832 
(PBS treatment). mCherry signal is detectable and indicates ES cell growth. GCV treatment began 3 833 
weeks post-injection following an initial PBS treatment. j, Fundoscopy, OCT and fluorescence imaging 834 
of eyes receiving only FS-RPE cells (4-week GCV treatment). This demonstrates that GCV treatment 835 
did not affect the RPE cells. k, Fundoscopy, OCT and fluorescence imaging of eyes receiving only FS-836 
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RPE cells (4-week PBS treatment). l, Fundoscopy, OCT and fluorescence imaging of eyes receiving 837 
only HAMC (4-week GCV treatment). 838 
Supplementary Calculation 1
The E↵ect of Aliquoting on FSL Calculation
We consider a pool of N = 2n cells that has FSLp = 1/p for some p 2 (0, 1). This means
p is the probability that the pool of cells is not FS. Below we calculate first the probability
that a randomly selected cell aliquot of size M = 2m, m < n is FS, i.e., the probability that it
contains only FS cells.
In our model the pool can have 2k non-FS cells with probability pk, for k = 0, 1, ..., n, such
that pk+1 = pk/2 for k = 0, 1, 2, 3, ..., n  1. Thus
pk = pk 1/2 = pk 2/22 = ... = p0/2k,
for k = 1, 2, ..., n, and since 1  p is the probability that the pool is FS, we have
1 = 1  p+
nX
j=0
pk = 1  p+ p0(1 + 2 1 + ...+ 2 n) = 1  p+ p0(2  2 n).
Hence
p0 =
p
2  2 n , pk = p2
 k(2  2 n) 1, k = 0, 1, ..., n.
Let qa denote the probability that the aliquot is FS, and let qa|k denote the conditional prob-
ability that the aliquot is FS given that the pool has 2k non-FS cells. Clearly, the conditional
probability that the aliquot is FS, given that the pool is FS, is 1, and qa|k = 0 if N   2k < M ,
i.e., when k   n. Thus by the law of total probability
qa = 1  p+
nX
k=0
pkqa|k = 1  p+ p
n 1X
k=0
2 k(2  2 n) 1qa|k. (1)
It remains to calculate qa|k. To this end we imagine that we choose M cells randomly, consec-
utively and without replacement, from a pool of size N which has K := 2k non-FS cells. The
probabilities that the first chosen cell is FS, the second chosen cell is FS and that the j-th
chosen cell is FS, are N KN ,
N K 1
N 1 and
N K j+1
N j+1 , respectively, for j < N  K. Hence
qa|k = N KN ⇥ N K 1N 1 ⇥ · · ·⇥ N K M+1N M+1 = ⇧M 1j=0 N K jN j . (2)
Note that this value is the same as
 
N K
M
 
divided by
 
N
M
 
, which is immediately understandable
by viewing the selection as randomly choosing M cells out of N . The number of all, equally
probable selections is
 
N
M
 
, and among them
 
N K
M
 
are FS aliquots.
Now we calculate FSLap, the FSL of the randomly chosen aliquot. Using that FSLap =
1/(1  qa), FSLp = 1/p and 1  p = (FSLp   1)/FSLp, from equation (1) we get
FSLap =
FSLp
1 Pn 1k=0 2 k(2  2 n) 1qa|k . (3)
Notice that the contribution of the terms 2 k(2   2 n) 1qa|k in the summation of the above
expression is negligible for large k. Therefore we get a good approximation for FSLap if we
keep only the terms with k < m. In this case we can simplify expression (2) for qa|k by
(N  K)⇥ (N  K   1)⇥ ...⇥ (N  M + 1)
to get
qa|k = N MN ⇥ N M 1N 1 ⇥ N M 2N 2 ⇥ ...⇥ N M K+1N K+1 = ⇧K 1j=0 N M jN j . (4)
It is clear that
N M j
N j <
N M
N =
A 1
A ,
1
2where A = N/M is the number of aliquots generated from the pool of cells. Thus for K :=
2k < M = 2m we can approximate qa|k from above by 
A 1
A
 2k
,
and from (3) we get the approximation
FSLap ⇡ FSLp
1 Pm 1k=0 2 k 1(A 1A )2k . (5)
We note that this approximation is very good in practice for the range of M and N that we
are using, when M is essentially smaller than N , which is more than a million.
Finally we calculate the ratio FSLap/FSLa, called FSL drop, where FSLa denotes the FSL
of a separately produced pool with the same cell number M as that of the aliquot. By our
observations, in the clinically relevant range, the logarithm of the FSL is approximately a
linear function of the logarithm of the cell number of the pool, with slope close to minus one.
This means, that in the clinically relevant range of cell numbers we have
FSLp
FSLa
⇡ M
N
=
1
A
.
Consequently, from (5) we obtain
FSLap
FSLa
⇡ 1
A
 
1 Pm 1k=0 2 k 1(A 1A )2k  . (6)
The contribution of those terms of the sum in this formula, which correspond to large k, is
very small. In other words, for large M only the first few terms (i.e. 15) of the sum should be
considered, since the contribution of the other terms is negligible. This means, that practically
the FSL drop depends only on the number of aliquots A, when the cell numbers of the aliquot
and of the pool are su ciently large. To make this argument more precise let dm denote the
right-hand side of (6) and estimate the error "l = dl   dm that we make when we sum the
terms until l   1 < m  1 in place of m  1 in (6). Clearly, for any l < m we have
"l =
1
A
 
(1  Sm) 1   (1  Sl) 1
   Sm   Sl
A(1  Sm)2 <
tl
A(1  S)2 , (7)
where for integers j   0 we use the notations
Sj :=
jX
k=0
2 k 1(A 1A )
2k , S :=
1X
k=0
2 k 1(A 1A )
2k , tj :=
1X
k=j+1
2 k 1(A 1A )
2k .
Since f(x) = 2 xr 2x is a decreasing function of x 2 [0,1) for any r   1, we get
tl  1
2
Z 1
l
2 xr 2
x
dx =
1
2 ln 2
Z 1
2l
y 2r y dy  2
 2l
2 ln 2
Z 1
2l
r y dy =
2 2l 1
ln r ln 2
r 2
l
, (8)
with r := A/(A  1). Notice that for every j   0
1  S   1 
jX
k=0
2 k 1   tj = 2 j 1   2 2j 1(ln r ln 2) 1r 2j = 2 j 1(1  2 j(ln r ln 2) 1r 2j).
Thus choosing the smallest integer j = j0 such that j0   1  log2(ln r ln 2), we get
1  S   2 j0 2   2 3(ln r ln 2)
for all A   2. Thus we have
(1  S)2   2 6(ln r ln 2)2.
3Using this together with estimate (8), from (7) we obtain
"l <
1
A(ln 2 ln r)32
 2l+6r 2
l
for all l  m and A   2, where r = A/(A  1). Hence by the simple estimate
ln r = ln(1 + (A  1) 1)   ln 2(A  1) 1,
valid for all A   2, and since (ln 2) 6 < 10, we get
"l < 10
(A 1)3
A 2
 2l+6r 2
l
< 10A22 2l+6r 2
l
.
Thus we can see that even for relatively large A, say A = 512, the error is negligible if m > 15
is replaced with 15 in the calculation of the FSL drop by the formula (6).
